epoetin alfa, Epogen, Procrit (cont.)
Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
Treatment with epoetin alfa may increase the growth of several types of cancer and reduce survival, and, therefore, its use should be restricted to the conditions discussed previously.
GENERIC AVAILABLE: No
PREPARATIONS: Vials containing liquid for injection: 2000, 3000, 4000, 10000, 20000 and 40000 U/ml as well as 20000 U/2ml
STORAGE: Epoetin alfa should be stored at 2 C - 8 C (36 F - 46 F). It should not be frozen. Multiple-use vials should be used within 21 days of the first use.
DOSING: Epoetin alfa is administered intravenously or subcutaneously (under the skin) at 50-100 units/kg of body weight, three times weekly. The dose is tailored to each patient based on targeted hemoglobin levels. Adult patients with cancer receiving chemotherapy may be treated with 40,000 units weekly or 150 units/kg 3 times weekly.
Zidovudine treated patients should receive 100 units/kg 3 times weekly.
Surgery patients should receive 300 units/kg per day daily for 14 days or 600 units/kg weekly. The smallest effective dose should be used.
In clinical trials, the risk of death or serious heart problems, and stroke occurred more often when epoetin alpha was administered to target a hemoglobin level greater than 11 g/dL. Epoetin alfa vials should not be shaken since the drug may be damaged, and bubbles may form that prevent some of the drug from being drawn up into the syringe during injection. Iron stores should be evaluated before therapy and supplemental iron should be administered if needed.
DRUG INTERACTIONS: No clinical studies have been done to demonstrate epoetin alfa drug interactions.
PREGNANCY: There are no studies of epoetin alfa use in pregnant women. Polyhydramnios and intrauterine growth restriction was reported in a small number of pregnant women who received epoetin alpha. Multiple dose vials contain benzyl alcohol and should not be administered to pregnant women.
NURSING MOTHERS: It is not known if epoetin alfa is excreted into breast milk. Multiple dose vials contain benzyl alcohol and should not be administered to nursing mothers.
Medically reviewed by Eni Williams, PharmD
Reference: FDA Prescribing Information
Medically Reviewed by a Doctor on 4/3/2015
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index